Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Drug Development
Small Molecule Research & Development
Fierce 50
Special Report
Awards Gala
Awards
Outsourcing Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Subscribe
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Drug Development
Small Molecule Research & Development
Fierce 50
Special Report
Awards Gala
Awards
Outsourcing Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
OrbiMed
Biotech
Windward breezes toward phase 3 with $165M for TSLP ambitions
The cash infusion is meant to accelerate the development of the company’s lead candidate, a twice-yearly anti-TSLP antibody, into phase 3.
Angus Liu
May 4, 2026 10:31am
OrbiMed’s Sidewinder slithers ahead with $137M series B for ADCs
Apr 8, 2026 7:00am
OrbiMed-backed Pinnacle adds $89M for oral peptides
Mar 26, 2026 10:29am
AirNexis swoops in with $200M series A for COPD asset
Jan 9, 2026 11:01am
Electra shines with $183M fundraise for rare disease trial
Oct 22, 2025 8:26am
Barinthus enters reverse merger with metabolic disease biotech
Sep 30, 2025 10:39am
